Interleukin 2 receptor expression by human blood lymphocytes after vaccination with pneumococcal polysaccharides.
Proliferative responses of unseparated peripheral blood mononuclear cells (PBMC) and blood T cells to recombinant interleukin 2 (rIL-2) were significantly increased 7-21 days after the vaccination with pneumococcal polysaccharides (PPS). In contrast, non-T cells expressed increased responsiveness to rIL-2 only on post-vaccination day 7. Analysis of the proliferative response to rIL-2 among lymphocyte subsets (CD4+Leu8+, CD4+Leu8-, CD8+Leu8+, CD8+Leu8-, CD20+) in cultures of unseparated PBMC revealed that the CD8+Leu8- T cells expressed increased responsiveness 7-14 days after vaccination, whereas neither CD4+ (Leu8+ and Leu8-) nor CD8+Leu8+ T cells showed significantly increased responsiveness after vaccination. The CD20+ B cells, like non-T cells, expressed increased responsiveness to rIL-27 days after the vaccination only. Expression of the 55 kD low-affinity interleukin 2 receptor (IL-2R, CD 25) on freshly isolated PBMC, as judged by direct fluorescence staining with a MoAb anti-55 kD chain, was low (less than 3%) and an increased expression of this receptor was not detected following vaccination. In contrast, binding of 125I-labelled IL-2 to freshly isolated PBMC increased following vaccination (day 7). Scatchard plot analysis revealed a modest increase in the expression of high-affinity IL-2R (Kd = 1-2 pM), whereas the increase in expression of the 75-kD, intermediate-affinity IL-2R (Kd = 300 pM) was more pronounced (from 195 to 295 (means) receptors per PBMC). It is concluded that, following vaccination with PPS increased IL-2R expression is induced on blood lymphocytes. These investigations suggest a role for T cells in the human immune response against PPS.
Tvede
N
N
Department of Medicine TTA, Rigshospitalet, Copenhagen, Denmark.
Heilmann
C
C
Christensen
L D
LD
D000328:Adult; D000945:Antigens, Differentiation, T-Lymphocyte; D001428:Bacterial Vaccines / Q000276:immunology*; D002478:Cells, Cultured; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000378:metabolism*; D008970:Molecular Weight; D022242:Pneumococcal Vaccines; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D011994:Recombinant Proteins / Q000494:pharmacology; D012542:Scattering, Radiation; D013296:Streptococcus pneumoniae / Q000276:immunology*; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism
D000945:Antigens, Differentiation, T-Lymphocyte; D001428:Bacterial Vaccines; D007376:Interleukin-2; D022242:Pneumococcal Vaccines; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D013936:Thymidine